Hillstream Enters Into An Exclusive Option Agreement To Acquire A Clinical Stage Asset For Chronic Pruritis; Terms Not Disclosed
Portfolio Pulse from Benzinga Newsdesk
Hillstream BioPharma Inc. has entered into an exclusive option agreement to acquire a clinical stage asset for chronic pruritis. The terms of the agreement have not been disclosed.
September 11, 2023 | 3:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Hillstream BioPharma's acquisition of a clinical stage asset for chronic pruritis could potentially expand its product portfolio and increase its market presence.
The acquisition of a clinical stage asset for chronic pruritis by Hillstream BioPharma could potentially expand its product portfolio and increase its market presence. This could lead to increased revenues and profitability in the future, which could positively impact the company's stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100